PH12012502411A1 - Method of modulating stress-activated protein kinase system - Google Patents

Method of modulating stress-activated protein kinase system

Info

Publication number
PH12012502411A1
PH12012502411A1 PH1/2012/502411A PH12012502411A PH12012502411A1 PH 12012502411 A1 PH12012502411 A1 PH 12012502411A1 PH 12012502411 A PH12012502411 A PH 12012502411A PH 12012502411 A1 PH12012502411 A1 PH 12012502411A1
Authority
PH
Philippines
Prior art keywords
protein kinase
activated protein
modulating
sapk
kinase system
Prior art date
Application number
PH1/2012/502411A
Other languages
English (en)
Inventor
Leonid Beigelman
Lawrence M Blatt
Ramachandran Radhakrishnan
Scott D Seiwert
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of PH12012502411A1 publication Critical patent/PH12012502411A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F289/00—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds not provided for in groups C08F251/00 - C08F287/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
PH1/2012/502411A 2005-05-10 2006-05-09 Method of modulating stress-activated protein kinase system PH12012502411A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67947105P 2005-05-10 2005-05-10
US73223005P 2005-11-01 2005-11-01
PCT/US2006/017988 WO2006122154A2 (en) 2005-05-10 2006-05-09 Pyridone derivatives for modulating stress-activated protein kinase system

Publications (1)

Publication Number Publication Date
PH12012502411A1 true PH12012502411A1 (en) 2019-07-17

Family

ID=36954420

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/502411A PH12012502411A1 (en) 2005-05-10 2006-05-09 Method of modulating stress-activated protein kinase system

Country Status (26)

Country Link
US (5) US7728013B2 (enExample)
EP (2) EP2591784B1 (enExample)
JP (3) JP2008544743A (enExample)
KR (1) KR20080023680A (enExample)
CN (1) CN103012254A (enExample)
AP (1) AP2007004244A0 (enExample)
AU (1) AU2006244072B2 (enExample)
BR (1) BRPI0608907A2 (enExample)
CA (1) CA2608116A1 (enExample)
DK (1) DK1928454T3 (enExample)
EA (1) EA015252B1 (enExample)
ES (2) ES2524922T3 (enExample)
GE (1) GEP20115364B (enExample)
HR (1) HRP20141053T1 (enExample)
IL (1) IL186731A0 (enExample)
MA (1) MA29499B1 (enExample)
MX (1) MX2007014114A (enExample)
NI (1) NI200700289A (enExample)
NO (1) NO20075646L (enExample)
PH (1) PH12012502411A1 (enExample)
PL (1) PL1928454T3 (enExample)
PT (1) PT1928454E (enExample)
RS (1) RS53599B1 (enExample)
SI (1) SI1928454T1 (enExample)
TN (1) TNSN07416A1 (enExample)
WO (1) WO2006122154A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
TW200904421A (en) 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
WO2010065755A1 (en) * 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20100190731A1 (en) * 2009-01-26 2010-07-29 Jeff Olgin Methods for treating acute myocardial infarctions and associated disorders
WO2010135470A1 (en) * 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma
JP5722883B2 (ja) * 2009-05-25 2015-05-27 中南大学Ｃｅｎｔｒａｌ Ｓｏｕｔｈ Ｕｎｉｖｅｒｓｉｔｙ １−（置換ベンジル）−５−トリフルオロメチル−２−（１ｈ）ピリドン化合物及びその塩、並びにその製造方法及びその用途
JP5583758B2 (ja) * 2009-05-25 2014-09-03 中南大学 １−（置換アリール）−５−トリフルオロメチル−２−（１ｈ）ピリドン化合物及びその塩、並びにその製造方法及びその用途
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
CA2806670A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2012225611B2 (en) 2011-03-08 2016-09-15 Auspex Pharmaceuticals, Inc. Substituted N-Aryl pyridinones
AU2012257347A1 (en) * 2011-05-17 2014-01-09 Joint Stock Company "Pharmasyntez" Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
EP2968292A4 (en) * 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
EP3007556B1 (en) 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
GB201319620D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2015229270B2 (en) 2014-03-12 2020-12-24 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
MX382781B (es) * 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
EP3154338B1 (en) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
CN106661635B (zh) 2014-06-26 2021-05-28 西奈山伊坎医学院 通过分析预示性基因集诊断亚临床和临床的急性排异的方法
AU2015279621B2 (en) 2014-06-26 2021-04-08 Icahn School Of Medicine At Mount Sinai Methods for diagnosing risk of renal allograft fibrosis and rejection
KR102787387B1 (ko) 2015-12-08 2025-03-26 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
AU2017251555B2 (en) * 2016-04-14 2021-04-29 Guangzhou Joyo Pharmatech Co., Ltd Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases
CN106083817B (zh) * 2016-06-14 2019-01-18 四川大学 吡非尼酮衍生物及其制备方法
CN107556234A (zh) * 2016-06-30 2018-01-09 陕西合成药业股份有限公司 一种新型吡啶酮类化合物及其制备方法和在医学上的应用
CN106748984A (zh) * 2016-11-22 2017-05-31 斯芬克司药物研发（天津）股份有限公司 6‑羟甲基‑1‑苯基吡啶‑2‑酮及其制备方法与应用
CA3108048A1 (en) * 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
BR112020019972A2 (pt) 2018-04-16 2021-01-05 Icahn School Of Medicine At Mount Sinai Métodos para identificar um receptor de aloenxerto renal e para identificar um receptor de aloenxerto renal em risco de rejeição aguda do aloenxerto antes do transplante, kit para identificar receptores de aloenxerto renal e método para selecionar um paciente com aloenxerto renal
WO2021211745A1 (en) * 2020-04-14 2021-10-21 Excalibur Pharmaceuticals, Inc. Pirfenidone for coronavirus treatment
WO2022240455A1 (en) * 2021-05-14 2022-11-17 The Johns Hopkins University Autoantibodies for use in identifying disease
CN118526493A (zh) * 2023-10-30 2024-08-23 大连理工大学 一类n-取代苯基-2-吡啶酮化合物在治疗癌症和缓解纤维化中的应用
KR20250122004A (ko) 2024-02-05 2025-08-13 재단법인 대구경북첨단의료산업진흥재단 신규한 eIF2B 작용제 및 이를 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (337)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1070639B (de) 1959-12-10 Farbenfabriken Bayer Aktiengesellschaft, Levenkusen-Bayerwerk Verfahren zur Herstellung von Peptiderj
CH312531A (de) 1952-06-20 1955-12-31 Ciba Geigy Verfahren zur Herstellung eines Pyridazons.
CH312530A (de) 1952-06-20 1955-12-31 Ciba Geigy Verfahren zur Herstellung eines Pyridazons.
GB788393A (en) 1953-04-30 1958-01-02 Ciba Ltd Process for the manufacture of pyridazone compounds
CH333366A (de) 1953-09-04 1958-10-15 Ciba Geigy Verfahren zur Herstellung neuer Pyridazone
DE1070639C2 (enExample) 1958-09-30 1964-04-16
US3014034A (en) 1959-01-22 1961-12-19 Ciba Pharm Prod Inc 1, 3-diaryl, 5-amino-pyridazinones
GB889317A (en) 1959-01-22 1962-02-14 Ciba Ltd New phenyl-diazines and a process for their manufacture
DE1936231U (de) 1965-12-06 1966-04-07 Anton Poettgens Betonruettelflasche.
JPS422264Y1 (enExample) 1966-08-10 1967-02-10
US3622340A (en) 1968-08-12 1971-11-23 Eastman Kodak Co 4-thiouracil compounds as fog inhibitors
UST866035I4 (en) 1969-05-05 1969-09-30 Defensive publication
BE787523A (fr) * 1971-08-13 1973-02-12 Chem Pharmac Fabrik Dr Hermann Medicament a base de pyridone-2
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
DE2366349C2 (de) 1972-12-18 1986-03-27 Affiliated Medical Research Inc., Princeton, N.J. Verfahren zur Herstellung von 5-Methyl-1-phenyl-2-(1H)-pyridon
AT333774B (de) 1974-09-24 1976-12-10 Chemie Linz Ag Verfahren zur herstellung von 3-phenylpyridazonen
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPS51128438A (en) 1975-04-26 1976-11-09 Yamanouchi Pharmaceut Co Ltd An antibacterial drug against fish diseases
DE2557342A1 (de) 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US4258052A (en) * 1976-08-17 1981-03-24 Yu Ruey J Treatment of psoriasis with nicotinamide analogues
DE2707268A1 (de) 1977-02-19 1978-08-31 Hoechst Ag Indol-3-carbaldehyd-oxime und verfahren zu ihrer herstellung
GB1596887A (en) 1977-07-15 1981-09-03 Rohm & Haas 2-pyridone derivatives and their use as plant growth regulators
JPS557201A (en) 1978-05-23 1980-01-19 Shionogi & Co Ltd Derivative of tetrahydrothiopyrano(2,3-b)indole
GB2042562B (en) 1979-02-05 1983-05-11 Sandoz Ltd Stabilising polymers
DD149666A1 (de) 1979-06-27 1981-07-22 Karl Gewald Verfahren zur herstellung von 6-amino-und 6-hydroxy-1-aryl-5-cyan-2(1h)-pyridinonen und-thionen
JPS5721388A (en) 1980-07-11 1982-02-04 Nippon Nohyaku Co Ltd Condensed pyrazole derivative
JPS5777671A (en) 1980-10-31 1982-05-15 Yasumitsu Tamura Preparation of hydroxyindoles ( or 1,4-dihydroisoquinolones) and their intermediate
US4404203A (en) 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4476307A (en) 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US4473696A (en) 1982-10-07 1984-09-25 Ici Americas Inc. Synthesis of 2-substituted-5-methyl-pyridines
US4645839A (en) 1982-12-17 1987-02-24 Ici Americas Inc. Sulphur dehydrogenation process to yield 5-methyl-2-pyridone
US4650804A (en) 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
US4576942A (en) 1984-07-12 1986-03-18 Usv Pharmaceutical Corp. Anti-allergic and anti-inflammatory bi- and tri- cyclo-1,4-thiazine derivatives, composition, and method of use therefor
US4760083A (en) 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
US5173489A (en) 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
GB8621217D0 (en) 1986-09-03 1986-10-08 Ici Plc Chemical compounds
DE3805746C2 (de) 1987-03-05 2003-04-10 Clariant Finance Bvi Ltd 1:2-Chromkomplexfarbstoffe
JPS63290821A (ja) 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
DK641487A (da) 1987-12-07 1989-06-08 Gluetech Aps Fremgangsmaade til modificering af polymeroverflader
DE3807295A1 (de) 1988-03-05 1989-09-14 Basf Ag Neue n-heteroaryl-tetrahydrophthalimidverbindungen
JP2614081B2 (ja) 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
US5019365A (en) 1988-11-29 1991-05-28 The Dow Chemical Company Quaternary polyamines as sulfite oxidation inhibitors
US5167941A (en) 1988-11-29 1992-12-01 The Dow Chemical Company Quaternary polyamines as sulfite oxidation inhibitors in amine scrubbing of SO2
GB8901836D0 (en) 1989-01-27 1989-03-15 Sobio Lab Compounds
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
US5077142A (en) 1989-04-20 1991-12-31 Ricoh Company, Ltd. Electroluminescent devices
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
JPH0343744A (ja) 1989-07-12 1991-02-25 Hitachi Chem Co Ltd 電子写真感光体
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
JPH05505610A (ja) 1990-03-27 1993-08-19 スミスクライン・ビーチャム・コーポレイション ５―リポキシゲナーゼ阻害剤
DE69131268T2 (de) 1990-09-21 1999-12-30 Rohm And Haas Co., Philadelphia Dihydropyridazinone und Pyridazinone als Fungizide
JPH04223457A (ja) 1990-12-26 1992-08-13 Konica Corp ハロゲン化銀写真感光材料
AU1191292A (en) 1991-02-11 1992-09-07 Schering Agrochemicals Limited Imidazole pesticides
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2103050A1 (en) 1991-05-15 1992-11-16 Yung-Chi Cheng Determination of prodrugs metabolizable by the liver and therapeutic use thereof
DE69115692T2 (de) 1991-09-10 1996-08-01 Agfa Gevaert Nv Thermisch übertragbare fluoreszierende Verbindungen
ES2113399T3 (es) 1991-12-26 1998-05-01 Mitsubishi Chem Corp Derivados de beta-oxo-beta-bencenopropano-tio-amida.
US5241065A (en) 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
AU4027693A (en) 1992-04-16 1993-11-18 Du Pont Merck Pharmaceutical Company, The Substituted nitrogen containing spiro compounds for use in treating cognitive deficits
AU4376893A (en) 1992-05-19 1993-12-13 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
DE4237656A1 (de) 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
CA2099743A1 (en) 1992-07-02 1994-01-03 Akihiko Ishida Pyridazinone derivatives and processes for preparing the same
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
US5356904A (en) 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
DE4242451A1 (de) 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
WO1994017059A1 (fr) 1993-01-29 1994-08-04 Nippon Soda Co., Ltd. Derive heterocyclique
JPH06256187A (ja) 1993-03-02 1994-09-13 Fujisawa Pharmaceut Co Ltd キノリジノン化合物またはその塩を含有する鎮咳・去痰剤
CA2161648A1 (en) * 1993-05-07 1994-11-24 Solomon B. Margolin Compositions and methods for reparation and prevention of fibrotic lesions
JP3507124B2 (ja) 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
DE4423934A1 (de) 1993-09-02 1995-03-09 Basf Ag 3(2H)-Pyridazinon-Derivate, Verfahren zu ihrer Herstellung und Verwendung
TW403741B (en) 1993-10-15 2000-09-01 Takeda Chemical Industries Ltd Triazine derivative, production and use thereof
JPH07128793A (ja) 1993-11-05 1995-05-19 Konica Corp 染料の固体微粒子分散物および該分散物を含有するハロゲン化銀写真感光材料
US5719155A (en) 1993-11-10 1998-02-17 Japan Tobacco Inc. Chroman derivative and pharmaceutical use thereof
JPH09506913A (ja) 1993-12-15 1997-07-08 スミスクライン・ビーチャム・コーポレイション 化合物および方法
JPH07233072A (ja) 1993-12-28 1995-09-05 Tanabe Seiyaku Co Ltd 医薬組成物
KR100386542B1 (ko) 1993-12-29 2003-10-11 후지사와 야꾸힝 고교 가부시키가이샤 피라졸로피리딘아데노신길항제
JP3781200B2 (ja) 1994-04-27 2006-05-31 コニカミノルタホールディングス株式会社 ハロゲン化銀写真感光材料の処理方法
JP3261641B2 (ja) 1994-04-28 2002-03-04 コニカ株式会社 ハロゲン化銀写真感光材料の処理方法
US5466697A (en) 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
JPH08134371A (ja) 1994-11-02 1996-05-28 Konica Corp 固体微粒子分散物及びハロゲン化銀写真感光材料及び画像形成方法
EP0717143A1 (de) 1994-12-16 1996-06-19 Lignozym GmbH Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6114353A (en) 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
JPH11501911A (ja) * 1995-03-03 1999-02-16 ビー マーゴリン、ソロモン サイトカイン成長因子の引き起こす疾病の治療
TW324008B (en) 1995-03-13 1998-01-01 Ishihara Sangyo Kaisha Pyridone sulfonylurea compound, its production process and weed killer containing such compound
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
WO1996033994A1 (en) 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Amino-substituted derivatives, process for the preparation thereof, and herbicide
DE19520613A1 (de) 1995-06-06 1996-12-12 Bayer Ag Phenylpyridazinone
JPH11509847A (ja) 1995-07-31 1999-08-31 ノボ ノルディスク アクティーゼルスカブ ヘテロ環式化合物、それらの調製及び使用
AU6514196A (en) 1995-07-31 1997-02-26 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
AR003978A1 (es) 1995-08-25 1998-09-30 Rohm & Haas Composiciones de acidos grasos y piridazinonas que tienen efectos fungitoxicos sinergicos y metodos para controlar hongos.
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
EP0866656B1 (en) * 1995-09-19 2007-04-25 MARGOLIN, Solomon B. Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors
DE19535501A1 (de) 1995-09-25 1997-03-27 Bayer Ag Pyridonmethidazofarbstoffe
JPH09249567A (ja) 1996-01-12 1997-09-22 Otsuka Pharmaceut Co Ltd 医薬組成物
JPH09204932A (ja) 1996-01-25 1997-08-05 Fujitsu Ltd リチウム二次電池用電解液及びリチウム二次電池
IT1286545B1 (it) 1996-02-09 1998-07-15 Antonio Guarna Derivati benzo(c) chinolizinici,loro preparazione ed uso come inibitori delle 5-alfa-riduttasi
JPH09244235A (ja) 1996-03-14 1997-09-19 Toshiba Corp アルカリ現像用レジスト
ATE223376T1 (de) 1996-03-29 2002-09-15 Merck Frosst Canada Inc Bisarylcyclobutenderivate als cyclooxygenasehemmer
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
JPH09319023A (ja) 1996-05-27 1997-12-12 Fuji Photo Film Co Ltd 感熱記録材料
ATE294174T1 (de) * 1996-06-10 2005-05-15 Merck & Co Inc Substituierte imidazole mit cytokinin- inhibirender wirkung
EP0929543B1 (en) 1996-09-26 2001-10-31 Syngenta Participations AG Herbicidal composition
US6121251A (en) 1996-10-11 2000-09-19 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19754348A1 (de) 1996-12-11 1998-06-18 Ciba Geigy Ag Neue Herbizide
AU5719598A (en) 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
DE19708928A1 (de) 1997-03-05 1998-09-10 Bayer Ag Substituierte aromatische Aminoverbindungen
DE19821263A1 (de) 1997-05-12 1998-11-19 Call Krimhild Enzymatisches Bleichsystem mit enzymwirkungsverstärkenden Verbindungen zur Behandlung von Textilien
EP0983334A1 (de) 1997-05-12 2000-03-08 Call, Krimhild Enzymatisches bleichsystem mit neuen enzymwirkungsverstärkenden verbindungen
DE19726241A1 (de) 1997-06-20 1998-12-24 Call Krimhild Erweitertes enzymatisches Multikomponentensystem zur Behandlung von Abwässern, zur Herstellung von Holzverbundstoffen, zum Deinken von Altpapier, Colour stripping von Altpapier, zum Einsatz als Oxidationssystem bei der organischen Synthese und zum Einsatz bei der Kohleverflüssigung
DE19729061A1 (de) 1997-07-08 1999-01-14 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
SE9702651D0 (sv) 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
DE19731784A1 (de) 1997-07-24 1999-02-04 Bayer Ag Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide
SE9702794D0 (sv) 1997-07-24 1997-07-24 Astra Pharma Prod New compounds
JPH1149755A (ja) 1997-07-30 1999-02-23 Nippon Kayaku Co Ltd 新規含窒素ヘテロ環誘導体およびそれを有効成分とする殺虫殺ダニ組成物
ITFI970193A1 (it) 1997-08-01 1999-02-01 Applied Research Systems Uso di derivati benzo(c) chinolizinici come regolatori della crescita delle piante e composizioni ad uso agricolo che contengono tali
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
EP1007515A1 (en) 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
WO1999010332A1 (en) 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
US6207697B1 (en) 1997-09-09 2001-03-27 Dupont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa
JPH1180952A (ja) 1997-09-10 1999-03-26 Chugai Ro Co Ltd 酸化物薄膜の活性化反応蒸着法
HUP0004151A3 (en) 1997-10-27 2001-12-28 Isk Americas Inc Concord Herbicidal substituted benzene derivatives, intermediates, preparation and use thereof
ES2172939T3 (es) 1997-11-21 2002-10-01 Astrazeneca Uk Ltd Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
SI1042293T1 (sl) 1997-12-19 2008-08-31 Amgen Inc Substituirane piridinske in piridazinske spojine in njihova farmacevtska uporaba
JPH11180952A (ja) 1997-12-19 1999-07-06 Maruho Co Ltd ２−オキシインドール誘導体
DE19803667A1 (de) 1998-01-30 1999-08-05 Max Planck Gesellschaft Verfahren zur Herstellung von 5-Alkoxy (bzw. 5-Aroxy) -2,3-dihydrofuran-2-onen
FR2774986A1 (fr) 1998-02-16 1999-08-20 Rhodia Chimie Sa Utilisation de pyrone(s) ou equivalent pour masquer des isocyanates, procede de masquage, isocyanates ainsi masques, composition en contenant, procede de revetement utilisant ces compositions, revetement aini obtenu
CA2322994A1 (en) 1998-03-17 1999-09-23 Solomon B. Margolin Topical antiseptic compositions and methods
KR20010042287A (ko) 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세린 프로테아제 억제제로서의 퀴놀론
CN1305466A (zh) 1998-04-09 2001-07-25 拜尔公司 取代的苯基哒嗪酮类化合物
IL139239A0 (en) 1998-04-27 2001-11-25 Centre Nat Rech Scient 3-(amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of hiv related diseases
DE69934224T2 (de) 1998-04-27 2007-10-04 Kumiai Chemical Industry Co., Ltd. 3-arylphenylsulfid-derivate und insektizide und mitizide
ATE342734T1 (de) 1998-06-01 2006-11-15 Astellas Pharma Inc Adenosin a1 antagonisten gegen männliche sterilität
FR2779429B1 (fr) 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
WO2000016775A1 (en) 1998-09-18 2000-03-30 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
WO2000025789A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. A method of treating endometriosis
KR200241724Y1 (ko) 1998-11-25 2001-09-25 윤종익 메탈가스케트의결합장치
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
DE19918725A1 (de) 1999-04-24 2000-10-26 Bayer Ag Substituierte N-Cyano-sulfonsäureanilide
BR0010349B1 (pt) 1999-05-07 2011-10-04 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
FR2797629B1 (fr) 1999-08-19 2001-09-21 Rhodia Chimie Sa Utilisation de pyrone(s) ou equivalent pour masquer des isocyanates, procede de masquage, isocyanates ainsi masques, composition en contenant, procede de revetement utilisant ces compositions, revetement ainsi obtenu
AT408223B (de) 1999-12-27 2001-09-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von oxindolen
HUP0204496A3 (en) 2000-01-20 2004-07-28 Eisai Co Ltd Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same
AU2001234690A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa
EP1263754A1 (en) 2000-02-01 2002-12-11 Millennium Pharmaceuticals, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1257550T3 (da) 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
GB0002740D0 (en) 2000-02-07 2000-03-29 Novartis Ag Organic compounds
AU2001230605A1 (en) * 2000-02-09 2001-08-20 Shionogi And Co., Ltd. Apoptosis inhibitor
KR20020081334A (ko) 2000-02-21 2002-10-26 시마르 인코포레이티드 간질 치료를 위한 조성물과 방법
US6924292B2 (en) 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
EP1272483A2 (en) 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
DE10024938A1 (de) 2000-05-19 2001-11-22 Bayer Ag Substituierte Iminoazine
AU2001258825A1 (en) 2000-05-29 2001-12-11 Shionogi And Co., Ltd. Method for labeling with tritium
NZ522773A (en) * 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
DE10034803A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Sulfonsäureanilide
HUP0700086A2 (en) 2000-08-11 2007-05-29 Eisai Co Ltd 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
US20020049211A1 (en) 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
CA2742411A1 (en) 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
EP1318995B1 (en) 2000-09-19 2006-03-08 Centre National De La Recherche Scientifique (Cnrs) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
CN1120151C (zh) 2000-10-24 2003-09-03 大连化学工业股份有限公司 制备内酰胺的方法
MXPA03004672A (es) 2000-10-27 2004-04-20 Dow Agrosciences Llc 4,5-dihidro-1,2,4-triazin-6-onas sustituidas, 1,2,4-triazin-6-onas sustituidas, y su uso como fungicidas e insecticidas.
WO2002040448A1 (en) 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Pyridone derivatives as ap2 inhibitors
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
US7160912B2 (en) 2000-12-26 2007-01-09 Dr.Reddy's Laboratories Ltd. Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them
CA2433158C (en) 2000-12-28 2011-05-10 Shionogi & Co., Ltd. Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
US7867516B2 (en) 2001-01-29 2011-01-11 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
DE10108995A1 (de) 2001-02-23 2002-09-05 Abbott Gmbh & Co Kg Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
WO2002085858A1 (en) 2001-04-20 2002-10-31 Asahi Glass Company, Limited Process for producing purified piperidine derivative
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
AU2002316180A1 (en) 2001-06-01 2002-12-16 The Regents Of The University Of California Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
JP4180254B2 (ja) 2001-06-29 2008-11-12 独立行政法人科学技術振興機構 窒素含有６員環の製造方法
JP2003021901A (ja) 2001-07-05 2003-01-24 Fuji Photo Film Co Ltd 感光性平版印刷版の光重合方法
WO2003014087A1 (fr) 2001-08-06 2003-02-20 Asahi Glass Company, Limited Procede de preparation de 5-methyl-1-phenyl-2(1h)-pyridinone
WO2003035650A1 (en) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
TWI330183B (enExample) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
CN1257901C (zh) 2001-11-08 2006-05-31 中国科学院上海药物研究所 一类四氢喹啉酮哌啶类化合物及其制备方法和用途
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB0129391D0 (en) 2001-12-07 2002-01-30 Syngenta Participations Ag Microbiocidal n-phenyl-n-[4-(4-pyridyl)-2-pyrimidin-2-yl]-amine derivatives
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
EP1470112A1 (en) 2002-01-18 2004-10-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
SI1490064T1 (sl) * 2002-02-14 2010-01-29 Pharmacia Corp Substituirani piridinoni kot modulatorji p38 MAP kinaze
JP2003238611A (ja) 2002-02-18 2003-08-27 Japan Polyolefins Co Ltd オレフィン類重合用触媒成分、オレフィン類重合用触媒及びポリオレフィン類の製造方法
ATE447971T1 (de) 2002-02-19 2009-11-15 Shionogi & Co Antipruriginosa
JP2003261535A (ja) 2002-03-08 2003-09-19 Mitsubishi Chemicals Corp ２−ヒドロキシ−５−メチルピリジンの製造方法
WO2003076405A1 (en) 2002-03-14 2003-09-18 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
WO2003082265A2 (en) 2002-04-02 2003-10-09 Fujisawa Pharmaceutical Co Pharmaceutical composition for treating or preventing virus infectious diseases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003229004A1 (en) 2002-05-13 2003-12-02 Merck & Co., Inc. Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
MXPA04012440A (es) 2002-06-12 2005-04-28 Abbott Lab Antagonistas de receptor de hormona concentradora de melanina.
US20040006135A1 (en) 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
DE60336735D1 (de) 2002-07-22 2011-05-26 Orchid Res Lab Ltd Neue biologischaktive molekü le
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
BR0313459A (pt) 2002-08-13 2005-06-21 Warner Lambert Co Derivados monocìclicos como inibidores de metaloproteinases de matriz
JP2006502152A (ja) 2002-08-28 2006-01-19 インターミューン インコーポレイテッド 線維性疾患治療用の併用療法
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
CH696420A5 (de) * 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
WO2004031145A2 (en) 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
JP4542743B2 (ja) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US20040142950A1 (en) 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US20040157738A1 (en) 2003-02-12 2004-08-12 Ishihara Sangyo Kaisha, Ltd. Novel oxygen containing fused cyclic derivatives and herbicidal, desiccant and defoliate compositions containing them
CA2515939A1 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
US7012088B2 (en) 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
MXPA05009182A (es) 2003-02-28 2006-05-19 Dekk Tec Inc Modulador de resonancia para diagnostico y terapia.
WO2005013917A2 (en) 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
JP2004269469A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
JP4699358B2 (ja) 2003-04-08 2011-06-08 ビーエーエスエフ ソシエタス・ヨーロピア 除草剤又は乾燥性及び／若しくは落葉性化合物としてのベンゼンスルホンアミド誘導体
JP4089491B2 (ja) 2003-04-14 2008-05-28 コニカミノルタホールディングス株式会社 重合開始剤、重合組成物、ラジカル発生方法、平版印刷版材料および平版印刷版の作製方法
US20070032457A1 (en) 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
WO2004103296A2 (en) 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
WO2004105684A2 (en) * 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
JP2004359641A (ja) 2003-06-06 2004-12-24 Ono Pharmaceut Co Ltd Ｃｃｒ５活性化剤
US7521460B2 (en) 2003-06-20 2009-04-21 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
JP2005013152A (ja) 2003-06-27 2005-01-20 Asahi Kasei Corp 細胞分化抑制剤及びこれを用いた細胞培養方法、培養液、培養された細胞
US20050153941A1 (en) 2003-06-27 2005-07-14 Tomoyuki Miyabayashi Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
CA2529510A1 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005007632A1 (en) 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
ZA200600424B (en) 2003-08-01 2007-05-30 Genelabs Tech Inc Bicyclic imidazol derivatives against flaviviridae
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
MXPA06002499A (es) 2003-09-04 2006-06-20 Aventis Pharma Inc Indoles sustituidos como inhibidores de poli (adp-ribosa) polimerasa (parp).
EP1697342A2 (en) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
DE10345648A1 (de) 2003-10-01 2005-04-21 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von TMC-69-6H und verwandten Pyridonderivaten und deren Verwendung als Phosphatase-Inhibitoren
WO2005039598A1 (en) 2003-10-24 2005-05-06 Intermune, Inc. Method of treating alcoholic liver disease
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CA2545813C (en) * 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
JP4170198B2 (ja) 2003-11-14 2008-10-22 一丸ファルコス株式会社 化粧料組成物
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0416692A (pt) 2003-11-19 2007-01-30 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de emprego destes
US20070105890A1 (en) 2003-11-26 2007-05-10 Dainippon Sumitomo Pharma Co., Ltd Novel condensed imidazole derivative
JP5023492B2 (ja) 2003-12-05 2012-09-12 小野薬品工業株式会社 馬尾神経組織血流増加剤
DE10358004A1 (de) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
ES2299995T3 (es) 2004-01-29 2008-06-01 Pfizer, Inc. Derivados de 1-isopropil-2-oxo-1,2-dihidropiridina-3-carboxamida con actividad agonista de receptor 5-ht4.
GB0402812D0 (en) 2004-02-09 2004-03-10 Tanabe Seiyaku Co Novel compounds
JP2005255675A (ja) 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd 医薬組成物
US7872123B2 (en) 2004-02-20 2011-01-18 Japan Science And Technology Agency Process of making α-aminooxyketone/α-aminooxyaldehyde and α-hydroxyketone/α-hydroxyaldehyde compounds and a process making reaction products from cyclic α,β-unsaturated ketone substrates and nitroso substrates
CA2558272C (en) 2004-03-05 2011-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
MY143245A (en) 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
US20080081825A1 (en) 2004-04-28 2008-04-03 Hisao Nakai Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CA2565437A1 (en) 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2006011024A2 (en) 2004-07-19 2006-02-02 Glenmark Pharmaceuticals Ltd. New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
WO2006017443A2 (en) 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
EP1786803A1 (en) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DK1809622T3 (da) 2004-09-22 2010-11-08 Janssen Pharmaceutica Nv Inhibitorer af interaktionen mellem MDM2 og P53
US20060069260A1 (en) 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
ATE512144T1 (de) 2004-10-12 2011-06-15 Decode Genetics Ehf Peri-substituierte bicyclische arylsulfonamide gegen arterielle verschlusskrankheiten
TW200843761A (en) 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
US20060206269A1 (en) 2004-11-19 2006-09-14 Pharmacopeia Drug Discovery, Inc. One-dimensional QSAR models
CN101048383A (zh) 2004-11-23 2007-10-03 惠氏公司 促性腺激素释放激素受体拮抗剂
CN101098855B (zh) 2004-11-24 2012-06-06 沃泰克斯药物股份有限公司 3-[2-(3-酰氨基-2-氧代-2h-吡啶-1-基)-乙酰氨基]-4-氧代-戊酸衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
CA2587178A1 (en) 2004-11-24 2006-06-01 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
WO2006060122A2 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
US8158652B2 (en) * 2004-12-01 2012-04-17 Msd K.K. Substituted pyridone derivative
AU2005316396A1 (en) 2004-12-17 2006-06-22 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
WO2006076681A2 (en) 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006079021A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
CN1676518B (zh) 2005-03-17 2010-05-12 南开大学 4-取代苯基哒嗪类化合物及除草活性
WO2006107860A2 (en) 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches
EP1888812A1 (de) 2005-04-11 2008-02-20 Alcan Technology & Management Ltd. Verfahren zur verbesserung der barriereeigenschaften keramischer sperrschichten
CN1846699A (zh) 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
US8350043B2 (en) 2005-06-07 2013-01-08 Pharmacopeia, Inc. Azinone and diazinone V3 inhibitors for depression and stress disorders
MX2007015419A (es) 2005-06-08 2008-02-21 Novartis Ag Compuestos organicos.
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20060287319A1 (en) 2005-06-15 2006-12-21 Shibo Jiang Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
EP1898897A2 (en) 2005-07-07 2008-03-19 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
CA2626742A1 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP1960405A2 (en) 2005-11-23 2008-08-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
NZ568666A (en) 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
US7709501B2 (en) 2005-12-23 2010-05-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
CA2644716A1 (en) 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
ATE470665T1 (de) 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
EP2010488A2 (en) 2006-04-05 2009-01-07 Vitae Pharmaceuticals, Inc. Renin inhibitors
US20090275581A1 (en) 2006-04-05 2009-11-05 Baldwin John J Renin inhibitors
CN101460634A (zh) 2006-04-13 2009-06-17 康乃尔研究基金会有限公司 用于靶向c-rel的方法和组合物
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007127475A2 (en) 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
EA015942B1 (ru) 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法

Also Published As

Publication number Publication date
JP2012121931A (ja) 2012-06-28
CA2608116A1 (en) 2006-11-16
BRPI0608907A2 (pt) 2010-02-17
MX2007014114A (es) 2008-03-14
TNSN07416A1 (en) 2009-03-17
US8741936B2 (en) 2014-06-03
US9527816B2 (en) 2016-12-27
AU2006244072A1 (en) 2006-11-16
NI200700289A (es) 2008-06-17
DK1928454T3 (da) 2014-11-03
KR20080023680A (ko) 2008-03-14
AU2006244072B2 (en) 2012-09-20
RS53599B1 (sr) 2015-02-27
ES2524922T3 (es) 2014-12-15
JP5735931B2 (ja) 2015-06-17
US20140228310A1 (en) 2014-08-14
EP2591784B1 (en) 2016-09-14
US20060270612A1 (en) 2006-11-30
JP2012125254A (ja) 2012-07-05
US20100240704A1 (en) 2010-09-23
JP2008544743A (ja) 2008-12-11
EP2591784A1 (en) 2013-05-15
US20120258924A1 (en) 2012-10-11
AP2007004244A0 (en) 2007-12-31
US10010536B2 (en) 2018-07-03
US7728013B2 (en) 2010-06-01
WO2006122154A2 (en) 2006-11-16
WO2006122154A3 (en) 2007-07-26
EA200702452A1 (ru) 2008-06-30
GEP20115364B (en) 2011-12-26
EP1928454B1 (en) 2014-09-24
US20170095462A1 (en) 2017-04-06
EP1928454A2 (en) 2008-06-11
CN103012254A (zh) 2013-04-03
NO20075646L (no) 2007-12-07
AU2006244072A2 (en) 2009-03-26
IL186731A0 (en) 2008-06-05
SI1928454T1 (sl) 2015-01-30
EA015252B1 (ru) 2011-06-30
HRP20141053T1 (hr) 2014-12-19
PL1928454T3 (pl) 2015-03-31
MA29499B1 (fr) 2008-05-02
ES2600460T3 (es) 2017-02-09
PT1928454E (pt) 2014-12-04

Similar Documents

Publication Publication Date Title
PH12012502411A1 (en) Method of modulating stress-activated protein kinase system
MX2010012848A (es) Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
WO2007025090A3 (en) Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
IL165434A0 (en) Compounds having DPP-IV inhibitory activity
WO2006110816A3 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
NO20053340D0 (no) Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1).
TW200620490A (en) Method of forming a thin film component
WO2006044687A3 (en) Kinase inhibitors
MXPA06012796A (es) Ciertas entidades quimicas, composiciones y metodos.
ECSP077996A (es) Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
WO2009023773A3 (en) Galactokinase inhibitors
WO2007062167A3 (en) Method of modulating stress-activated protein kinase system
TN2009000151A1 (en) Mapk/erk kinase inhibitors
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
WO2007019182A3 (en) Methods and systems for high confidence utilization of datasets
EP1650194A4 (en) INHIBITOR OF PROTEIN KINASE
WO2005081960A3 (en) Inhibitors of protein tyrosine phosphatase 1b
WO2005027856A3 (en) Inhibitors of anthrax lethal factor
WO2004043400A3 (en) Peptide deformylase activated prodrugs